Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX ® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
LOS ANGELES, August 27, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® (daratumumab) in combination with lenalidomide (Revlimid®), bortezomib (VELCADE®) and dexamethasone (DARZALEX®-RVd), followed by maintenance therapy with DARZALEX®-lenalidomide (R), compared to RVd followed by maintenance therapy with R alone, in patients with newly diagnosed, transplant-eligible multiple myeloma. Data were presented in the plenary session at the 19th International Myeloma Society (IMS)...
Source: Johnson and Johnson - August 28, 2022 Category: Pharmaceuticals Source Type: news
Children could suffer from long-term eye problems due to too much screen time
A third of children are spending more than five hours a day on their screens over the summer holidays - which could cause long-term eye damage, experts have warned. A study of 1,500 parents found four in ten were completely unaware that extended periods using gadgets, such as tablets or phones, can be a leading cause for eye problems, like myopia - commonly known as short-sightedness. (Source: Daily Express - Health)
Source: Daily Express - Health - August 24, 2022 Category: Consumer Health News Source Type: news
Oral Supplement for Childhood Myopia: Preliminary Data Promising
(MedPage Today) -- Oral intake of 7-methylxanthine (7-MX) was associated with reduced myopia progression and axial elongation in children, according to a retrospective study from Denmark, where the caffeine metabolite is authorized for myopia control... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - August 24, 2022 Category: Pediatrics Source Type: news
7-Methylxanthine Linked to Reduced Myopia Progression in Children
TUESDAY, Aug. 23, 2022 -- For myopic children, the caffeine metabolite 7-methylxanthine (7-MX) is associated with reduced myopia progression and reduced axial elongation, according to a study published online Aug. 22 in the British Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 23, 2022 Category: Pharmaceuticals Source Type: news
Study suggests new way to slow worsening of kids' nearsightedness
If it's proven to be safe and effective in large clinical trials, a metabolite of caffeine may prove valuable in slowing the progression of short-sightedness, or myopia, in children. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 22, 2022 Category: Consumer Health News Source Type: news
Myopia: A Silent and Growing Epidemic Myopia: A Silent and Growing Epidemic
The proportion of adults who are nearsighted may be as high as 60% by 2050, according to experts. Yet public awareness about risk factors and preventive measures is low.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - July 14, 2022 Category: Internal Medicine Tags: Ophthalmology News Source Type: news
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
The Holocaust and disciplinary myopia in criminology and sociology: social injury as a response to the challenges of legal formalism - Dallier DJ.
Criminological and sociological discourse recognizes the impact of structure on crime, but generally eschews the consideration of structural damage and human suffering emanating from malevolent social movements (e.g., the Holocaust). Legal formalism presen... (Source: SafetyLit)
Source: SafetyLit - June 9, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Prison Reform Is Undermining Public Health and Safety
For a few months in the fall of 2021, reports of unchecked violence, abuse, and neglect at the jail on New York City’s Rikers Island were plastered across national news before receding back into the routinized cruelty that constitutes the underbelly of American life. This exceptional coverage of the brutality behind bars provoked universal condemnation. But in its short-lived ascent to the forefront of political discussions and popular media, this media “event” failed to account for the most unsettling reality at play: Rikers is everywhere.
Last week, while acknowledging that “people are dying&rdquo...
Source: TIME: Health - May 31, 2022 Category: Consumer Health News Authors: Eric Reinhart Tags: Uncategorized freelance healthscienceclimate justice Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
When Belle goes looking for Pip
I cannot imagine how cold it is in the seas off the coast of Britain at this time of year, but lots of people swim year round and my dog Belle (aka The Beeble) is no exception. Give her a beach with an easy access into the water and she’s off, ears flying as she throws herself into the waves.
This is pretty prosaic as pictures go, a dog in the water. But what could you do with it to make it more surreal or alternative? Is there anything you can’t see in the picture that suggests a bigger story?
You can see my effort here:
Belle flies out of the waves barking madly. Ears flying in all directions. She shakes all ...
Source: The Hysterectomy Association - May 12, 2022 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Creative Writing writing prompt Source Type: news
Experts Can ’t Agree on How Much Screen Time Is Too Much for Adults
The COVID-19 pandemic shifted our lives in myriad ways, including the amount of time we spent glued to our devices. Research published in 2021 found that Americans in their early twenties used their phones an average of 28.5 hours per week in 2020—up from 25.9 hours per week in 2018. One review of studies conducted in 2020 and 2021 put the estimates even higher, finding that average screen time for adults in the U.S. and other countries increased 60–80% from before the pandemic.
Excessive screen time has been shown to have negative effects on children and adolescents. It’s been linked to psychological pr...
Source: TIME: Health - May 9, 2022 Category: Consumer Health News Authors: Jamie Friedlander Serrano Tags: Uncategorized healthscienceclimate Mental Health Source Type: news
Contrast-Reducing Spectacles Could Slow Myopia Contrast-Reducing Spectacles Could Slow Myopia
Spectacles that reduce retinal contrast could slow the progression of myopia.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 4, 2022 Category: Allergy & Immunology Tags: Ophthalmology News Source Type: news
What's Better: Residual Hyperopia or Residual Myopia? What's Better: Residual Hyperopia or Residual Myopia?
Dr Garg discusses a paper from Dr Steven Schallhorn and colleagues on the effect of residual astigmatism on uncorrected visual acuity and patient satisfaction.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2022 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news
